Ana Alfonso Piérola

Medicine · Health Sciences

23h-index2.5kcitations190works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(98), Myeloproliferative Neoplasms: Diagnosis and Treatment(35), CAR-T cell therapy research(31), Multiple Myeloma Research and Treatments(23), Chronic Myeloid Leukemia Treatments(22)

Publications187 total

Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations
Transplantation and Cellular Therapy·2026
Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers
Blood·2025Open Access
Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma
Blood·2025
Single-cell DNA profiling unveils clonal evolution and identifies mechanisms of therapeutic resistance and progression in monoclonal gammopathies
Blood·2025Open Access
Targeted long-read sequencing with adaptive sampling in multiple myeloma: A pilot study toward a unified diagnostic platform
Blood·2025
Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)
Blood·2025Open Access
Integrated single-cell and spatial analysis identifies T cell exhaustion and adhesion signatures in early follicular lymphoma transformation
Blood·2025Open Access
Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations
Blood·2025· 1 cited
Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)
Blood·2025Open Access
Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations
Blood·2025· 1 citedOpen Access
Lineage-specific distribution of clonal hematopoiesis of indeterminate potential across mature hematopoietic subpopulations in cancer patients
Blood·2025
Efficacy and safety of CPX-351 in high-risk Acute Myeloid Leukemia
Blood·2025Open Access
Single-cell transcriptomics reveal long non-coding RNA dysregulation in PPP1R15B-EIF2A axis impairing erythroid maturation in myelodysplastic syndromes
Blood·2025Open Access
Absolute Lymphocyte Count (ALC) ≥1,000 IS AS A Surrogate of Car-T Cell Expansion and a Readily Available Biomarker to Predict Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2025
RAPID FIRE SESSION 02
Leukemia Research·2025
PROGNOSIS - PROGNOSTIC FACTORS OF OUTCOME AND RISK ASSESSMENT
Leukemia Research·2025
PLENARY SESSION 06: TREATMENT LOW RISK MDS (PART 1)
Leukemia Research·2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry
Leukemia·2025Open Access
AML-412: Bleximenib Dose Optimization and Determination of the Recommended Phase 2 Dose (RP2D) From a Phase 1 Study in Patients With Relapsed/Refractory Acute Leukemia (AL) With KMT2A and NPM1 Alterations
Clinical Lymphoma Myeloma & Leukemia·2025
AML-418: Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax+Azacitidine (VEN+AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
page 1 of 10Next →

Frequent Co-authors

Felipe Prósper(12), Guillermo Garcia‐Manero(11), Elias Jabbour(11), Ramón Lecumberri(9), Paula Rodríguez‐Otero(9), Tapan M. Kadia(9), Hagop M. Kantarjian(9), Patxi San Martín‐Úriz(8), Guillermo Montalban‐Bravo(8), Amaia Vilas‐Zornoza(7), Mikel Hernáez(7), Uwe Platzbecker(6), Diego Alignani(6), Farhad Ravandi(6), José A. Páramo(6), Juan Manuel Alonso‐Domínguez(5), Guillermo Serrano(5), Bruno Paiva(5), Jesús F. San Miguel(5), Koichi Takahashi(5)